| 摘要 |
The object of the present invention is the production of monoclonal antibodies (MCAs) that react with a high degree of selectivity to human breast cancer cells for a potential use in tumor diagnosis,prognosis and therapy. MCAs are produced by fusing Ns-l myeloma cells to spleen cells from BALB/c mice hyperimmunized with the wellcharacterized human breast carcinoma cell line BT-20. Hybridoma are selected on the basis of their preferential binding in an ELISA assay to human mammary tumor cells versus normal breast cells. Ammonium sulphate precipitation and ion-exchange chromatography allow the isolation of partially purified material that is further used as a possible tool to distinguish breast carcinoma cells from normal cells of the same histogenesis. According to the invention, three different techniques are used: ELISA, dot-immunobinding, and indirect immunofluorescence, to further characterize the antigen recognized by each of the MCAs produced. |
